Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jul;62(1):142–146. doi: 10.1038/bjc.1990.247

Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading.

G Blanco 1, K Holli 1, M Heikkinen 1, O P Kallioniemi 1, P Taskinen 1
PMCID: PMC1971734  PMID: 2390476

Abstract

Site of first recurrence, disease-free interval (DFI), female sex steroid receptors, ploidy measurements as well as histological grading have been analysed as potentially valuable predictive factors in 313 cases of recurrent breast cancer. Univariate and multivariate analyses show histological grading, site of recurrence and disease free interval to be useful prognostic variables when assessing prognosis once disease has recurred. High concentrations of oestrogen receptors (ER) were found in patients with bone metastases, whereas lower concentrations of ER were related to visceral recurrences. Ploidy measurements failed in this study to give any predictive information once disease recurred.

Full text

PDF
142

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aberizk W. J., Silver B., Henderson I. C., Cady B., Harris J. R. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer. 1986 Sep 15;58(6):1214–1218. doi: 10.1002/1097-0142(19860915)58:6<1214::aid-cncr2820580607>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  2. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bishop H. M., Blamey R. W., Elston C. W., Haybittle J. L., Nicholson R. I., Griffiths K. Relationship of oestrogen-receptor status to survival in breast cancer. Lancet. 1979 Aug 11;2(8137):283–284. doi: 10.1016/s0140-6736(79)90295-2. [DOI] [PubMed] [Google Scholar]
  4. Blamey R. W., Bishop H. M., Blake J. R., Doyle P. J., Elston C. W., Haybittle J. L., Nicholson R. I., Griffiths K. Relationship between primary breast tumor receptor status and patient survival. Cancer. 1980 Dec 15;46(12 Suppl):2765–2769. doi: 10.1002/1097-0142(19801215)46:12+<2765::aid-cncr2820461404>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  5. Blanco G., Alavaikko M., Ojala A., Collan Y., Heikkinen M., Hietanen T., Aine R., Taskinen P. J. Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients. Anticancer Res. 1984 Nov-Dec;4(6):383–389. [PubMed] [Google Scholar]
  6. Clark G. M., Sledge G. W., Jr, Osborne C. K., McGuire W. L. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987 Jan;5(1):55–61. doi: 10.1200/JCO.1987.5.1.55. [DOI] [PubMed] [Google Scholar]
  7. Cornelisse C. J., van de Velde C. J., Caspers R. J., Moolenaar A. J., Hermans J. DNA ploidy and survival in breast cancer patients. Cytometry. 1987 Mar;8(2):225–234. doi: 10.1002/cyto.990080217. [DOI] [PubMed] [Google Scholar]
  8. Cutler S. J., Ardyce J. A., Taylor S. G., 3rd Classification of patients with disseminated cancer of the breast. Cancer. 1969 Nov;24(5):861–869. doi: 10.1002/1097-0142(196911)24:5<861::aid-cncr2820240502>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  9. Devitt J. E. The enigmatic behavior of breast cancer. Cancer. 1971 Jan;27(1):12–17. doi: 10.1002/1097-0142(197101)27:1<12::aid-cncr2820270104>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  10. DiStefano A., Yong Yap Y., Hortobagyi G. N., Blumenschein G. R. The natural history of breast cancer patients with brain metastases. Cancer. 1979 Nov;44(5):1913–1918. doi: 10.1002/1097-0142(197911)44:5<1913::aid-cncr2820440554>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  11. Fey M. F., Brunner K. W., Sonntag R. W. Prognostic factors in metastatic breast cancer. Cancer Clin Trials. 1981 Fall;4(3):237–247. [PubMed] [Google Scholar]
  12. Fisher B., Bauer M., Wickerham D. L., Redmond C. K., Fisher E. R., Cruz A. B., Foster R., Gardner B., Lerner H., Margolese R. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983 Nov 1;52(9):1551–1557. doi: 10.1002/1097-0142(19831101)52:9<1551::aid-cncr2820520902>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  13. Fisher E. R., Sass R., Fisher B. Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure. Cancer. 1984 Feb 1;53(3 Suppl):712–723. doi: 10.1002/1097-0142(19840201)53:3+<712::aid-cncr2820531320>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  14. Hedley D. W., Rugg C. A., Ng A. B., Taylor I. W. Influence of cellular DNA content on disease-free survival of Stage II breast cancer patients. Cancer Res. 1984 Nov;44(11):5395–5398. [PubMed] [Google Scholar]
  15. Hietanen P., Miettinen M., Mäkinen J. Survival after first recurrence in breast cancer. Eur J Cancer Clin Oncol. 1986 Aug;22(8):913–919. doi: 10.1016/0277-5379(86)90056-8. [DOI] [PubMed] [Google Scholar]
  16. Kallioniemi O. P., Blanco G., Alavaikko M., Hietanen T., Mattila J., Lauslahti K., Koivula T. Tumour DNA ploidy as an independent prognostic factor in breast cancer. Br J Cancer. 1987 Nov;56(5):637–642. doi: 10.1038/bjc.1987.258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kallioniemi O. P., Blanco G., Alavaikko M., Hietanen T., Mattila J., Lauslahti K., Lehtinen M., Koivula T. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer. Cancer. 1988 Nov 15;62(10):2183–2190. doi: 10.1002/1097-0142(19881115)62:10<2183::aid-cncr2820621019>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  18. Kamby C., Rose C., Iversen H., Holm N. V., Andersen K. W., Thorpe S. M. Pattern of metastases in human breast carcinoma in relation to estrogen receptor status. Anticancer Res. 1986 Jan-Feb;6(1):107–111. [PubMed] [Google Scholar]
  19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  20. Mörz R., Francesconi M., Schemper M., Rainer H., Jakesz J., Moser K. The value of prognostic parameters for the stratification of advanced breast cancer patients. J Cancer Res Clin Oncol. 1982;102(3):289–299. doi: 10.1007/BF00411349. [DOI] [PubMed] [Google Scholar]
  21. Nash C. H., 3rd, Jones S. E., Moon T. E., Davis S. L., Salmon S. E. Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer. 1980 Dec 1;46(11):2380–2388. doi: 10.1002/1097-0142(19801201)46:11<2380::aid-cncr2820461113>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  22. Nikkanen T. A. Recurrence of breast cancer. A retrospective study of 569 cases in clinical stages I-III. Acta Chir Scand. 1981;147(4):239–245. [PubMed] [Google Scholar]
  23. Osborne C. K., Yochmowitz M. G., Knight W. A., 3rd, McGuire W. L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2884–2888. doi: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  24. Pater J. L., Mores D., Loeb M. Survival after recurrence of breast cancer. Can Med Assoc J. 1981 Jun 15;124(12):1591–1595. [PMC free article] [PubMed] [Google Scholar]
  25. Rosenman J., Perrone T. The metastasis-free interval following curative treatment for breast cancer. Int J Radiat Oncol Biol Phys. 1984 Jan;10(1):63–67. doi: 10.1016/0360-3016(84)90413-9. [DOI] [PubMed] [Google Scholar]
  26. Stewart J. F., King R. J., Sexton S. A., Millis R. R., Rubens R. D., Hayward J. L. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer. 1981 Apr;17(4):449–453. doi: 10.1016/0014-2964(81)90254-1. [DOI] [PubMed] [Google Scholar]
  27. Valagussa P., Brambilla C., Bonadonna G. Advanced breast cancer: are the traditional stratification parameters still of value when patients are treated with combination chemotherapy? Eur J Cancer. 1979 Apr;15(4):565–571. doi: 10.1016/0014-2964(79)90094-x. [DOI] [PubMed] [Google Scholar]
  28. Vihko R., Jänne O., Kontula K., Syrjälä P. Female sex steroid receptor status in primary and metastatic breast carcinoma and its relationship to serum steroid peptide hormone levels. Int J Cancer. 1980 Jul 15;26(1):13–21. doi: 10.1002/ijc.2910260104. [DOI] [PubMed] [Google Scholar]
  29. Wallgren A., Silfverswärd C., Eklund G. Prognostic factors in mammary carcinoma. Acta Radiol Ther Phys Biol. 1976 Feb;15(1):1–16. doi: 10.3109/02841867609132703. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES